DMAC vs SPGI · $157.4M cap vs P/E 27, rev $15.34B
DiaMedica Therapeutics Inc (DMAC) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
DMAC does not have a complete income-statement cache yet.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
DMAC currently screens at market cap $157.4M. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the DMAC and SPGI stock pages for the full models.
Not investment advice.